Hemolife

HemoLife is a clinical-stage biotechnology company specializing in the development of hemoglobin-based oxygen carriers (HBOCs) as artificial blood substitutes. The company's lead candidates are designed to provide immediate oxygen transport in cases of severe blood loss, trauma, or ischemia where real blood is unavailable or incompatible. HemoLife's technology focuses on stabilizing hemoglobin molecules through proprietary polymerization techniques to prevent renal toxicity while maintaining efficient oxygen release. Their pipeline includes applications for hemorrhagic shock, surgical support, and organ preservation. Headquartered in Suzhou, China, the company has secured significant investment from prominent venture capital firms to advance its platform through clinical trials. HemoLife aims to address the critical global shortage of donor blood and the logistical challenges of blood storage and cross-matching.